Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716937 | 0.83 | TMEM97 (0.57) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL14731911 | 0.81 | TMEM97 (0.71) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL14731842 | 0.81 | TMEM97 (0.64) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL16352695 | 0.81 | TMEM97 (0.71) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL16362506 | 0.81 | TMEM97 (0.71) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL14731917 | 0.81 | TMEM97 (0.71) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL14731718 | 0.80 | TMEM97 (0.74) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL14731712 | 0.79 | TMEM97 (0.72) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL14731732 | 0.79 | TMEM97 (0.68) | TMEM97KCNH2MEN1KMT2ASIGMAR1 | |
| SCHEMBL12436727 | 0.78 | SIGMAR1 (0.58) | TMEM97KCNH2MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2013029057-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | TMEM97 1/4885KCNH2 2420/4885MEN1 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.